The US Food & Drug Administration approved Axonics Modulation Technologies Inc.’s rechargeable sacral neuromodulation (r-SNM) system for treating chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments, Axonics announced on 9 September.
The FDA is also reviewing another PMA for r-SNM for the indications of overactive bladder – both urinary urgency incontinence and urinary urgency frequency – and urinary retention
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?